Bulgaria invests in cancer screening:
This article was originally published in Clinica
Executive Summary
Bulgaria is to allocate Lev1.7 million ($770,000) to a five-year cervical cancer screening programme. Some 650,000 women between the ages of 25 and 60 will be offered screening every three years. This is part of a cancer prevention programme aimed at reducing cervical, prostate and breast cancer. A further Lev10 million will be allocated to mammograms for annual checks of women aged 40-49 and every three years for women aged 50-69. Some 600,000 women will benefit. A total of Lev1.5 million will go towards annual prostate cancer examinations for men over 45.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.